NL-OMON19941Not yet recruitingNot Applicable
A controlled, randomized, double-blind nutritional study to assess the effects of milk processing and fat blend composition on stool consistency and protein and fat digestion in infants
FrieslandCampina0 sites300 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Healthy and term infants (gestational age >= 37 and <= 42 weeks)
- •- Infants who are partially formula fed (> 500 mL formula/day) or exclusively formula fed
Exclusion Criteria
- •- Congenital condition and/or previous or current illness that could interfere with study
- •- Known or increased risk of cow's milk allergy and/ or lactose intolerance (i.e. one of the biological parents and or siblings diagnosed with cow's milk allergy, asthma, hay fever, etc.)
Investigators
Similar Trials
Active, not recruiting
Phase 2
The efficacy and safety of a medical device sunscreen for the prevention and reduction of skin damage caused by excessive sun exposurePrevention and reduction of actinic keratosis in patients with epidermal skin damage and increase in skin qualitySkin and Connective Tissue DiseasesISRCTN907481123SKIN AS80
Completed
Not Applicable
A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhiniticsAllergic reaction10024970hay feverNL-OMON36044GlaxoSmithKline75
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo- controlled, flexible dose study to evaluate the effectiveness and safety of pramipexole IR (0.125 – 0.5mg/day) compared to placebo for 6 weeks in children and adolescents (age 6-17 years) who are diagnosed with Tourette’s DisorderTourette's SyndromeMedDRA version: 14.0Level: LLTClassification code 10044127Term: Tourette's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-004460-39-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.54
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette Disorder according to DSM-IV criteriaEUCTR2008-004460-39-DEBoehringer Ingelheim Pharma GmbH & Co. KG54
Completed
Not Applicable
A randomised, prospective, double-blind controlled study evaluating the effectiveness of spinal endoscopy with adhesiolysis for the treatment of chronic low back paiISRCTN16558617Institutional Review Board of Ambulatory Surgery Center (USA)83